Volume 20 (2022): Issue 3.5 (Mar 2022): Abstracts from the NCCN 2022 Virtual Annual Conference

in Journal of the National Comprehensive Cancer Network
Online ISSN:
1540-1413
Print ISSN:
1540-1405
Cover Journal of the National Comprehensive Cancer Network
Young Investigator Awards
YIA22-001: Development of hKIT Chimeric Antigen Receptor T-Cells as Dual Hematopoietic Stem Cell Transplantation Conditioning and Immunotherapeutic Agents for Cure of Pediatric Acute Myeloid Leukemia
YIA22-002: A Common Polymorphism in 3β-Hydroxysteroid Dehydrogenase Promotes Resistance to Radiotherapy in Prostate Cancer
YIA22-003: Quantifying Minimal Residual Disease in Patients With Small Cell Lung Cancer
YIA22-004: The Feasibility of a Digitized Peer-To-Peer Patient Support System for Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation
YIA22-005: A Randomized Trial of Choice Architecture and Mailed Colorectal Cancer Screening Outreach in a Community Health Setting
YIA22-006: Characterization of Transcription-Replication Conflicts in KRAS-driven Pancreatic Cancer
YIA22-007: Adaptive Nutrition and Exercise Weight loss (A-NEW) Study for Breast Cancer Survivors With Overweight or Obesity
YIA22-008: Identification of Biomarkers That Predict Responses to Immunotherapy in Merkel Cell Carcinoma
Best Practices in Implementation and Use of Clinical Practice Guidelines
BPI22-009: Providing Value-Based Care Using a Novel Cancer Clinical Pathways Tool Embedded in Electronic Health Record
BPI22-010: Applying FRAME to Code Modifications to a Community-Based Educational Intervention and Lung Cancer Screening Protocols Amidst the Covid-19 Pandemic
BPI22-011: Accreditation Systems Reduce Time to Treatment Delays; Three-Year Review of a South African Internationally Accredited Site
BPI22-012: How Long Will They Wait? Applying Updated NCCN Criteria to Previously Unqualified Patients Reveals Missed Opportunities for Personalized Cancer Risk Management
BPI22-013: Current Guidelines for Genetic Variant Identification, a Missed Opportunity?
BPI22-014: Independent Validation of the PREDICT Prognostication Tool in U.S. Breast Cancer Patients Using the National Cancer Database (NCDB)
BPI22-015: Analysis of NCCN-Preferred Treatment Regimen Ordering via an EHR-Embedded Decision Support Tool in a Community Oncology Practice
BPI22-016: Leveraging Best Practices in Tobacco Cessation for Cancer Patients: The Fox Chase Cancer Center (FCCC) Case Study
BPI22-017: An Assessment of the NAVIFY Guidelines Application Using Clinical Simulation Research Methods
BPI22-018: Experience of Patients With Smoldering Systemic Mastocytosis Treated With Avapritinib as Part of a Global Compassionate Use Program
BPI22-019: Guidelines and Recommendations for the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Cancer Patients
BPI22-020: Better Together: Why Palliative Care Should be Incorporated Early in Patients With Advanced Head and Neck Cancer
BPI22-021: Surveillance Mammography in Elderly Breast Cancer Survivors (Project Funded by Breast Cancer Research Foundation)
BPI22-022: Real World Adherence to Biomarker Testing Guidelines That Inform First-Line Treatment Decisions for Patients Newly Diagnosed With Metastatic Non-Small Cell Lung Cancer in the Community Setting
BPI22-023: Strategies to Prevent Unplanned Emergency Department (ED) Utilization in the COVID-19 Era
BPI22-024: Assessing the Adherence to Standard of Care With Durvalumab and Overcoming Barriers in the Treatment of Unresectable Stage III Non-Small Cell Lung Cancer: A Single Institution Retrospective Study
BPI22-025: The Timing of Screening Breast MRI and Mammography for Women With Genetic Predisposition for Cancer
Bioinformatics/Information Technology Sciences
Clinical Oncology
CLO22-032: Effect of COVID-19 Causing Treatment Delay in Cancer Patients Receiving Immune Checkpoint Inhibitors
CLO22-033: Clinicopathologic and Sociodemographic Factors Associated With Late Relapse Triple Negative Breast Cancer
CLO22-034: Subtotal Glossectomy. Functional Outcomes After Compartmental Tongue Resection and Reconstruction With Pectoralis Major Myocutaneous Flap
CLO22-035: Treatment Outcome of Ruxolitinib and Decitabine Combination Chemotherapy Among Transplant Ineligible Advanced Stage Myeloproliferative Neoplasm: A Meta-analysis
CLO22-036: The Role of Zoledronic Acid Administration Among Lymphoma Patients Receiving Chemotherapy: A Systematic Review
CLO22-037: Tumor Lysis Syndrome and Infectious Complications During Induction With Venetoclax Combined With Azacitidine or Decitabine in Patients With Acute Myeloid Leukemia
CLO22-038: A Study on Response and Patterns of Failure for Well Lateralised Tumors of Oral Cavity by Loco-Regional Radiation
CLO22-039: Clinical Implication of Perineural Invasion in Patients Treated With Radical Prostatectomy for Prostate Cancer
CLO22-041: A Phase 2 Study of Magrolimab Combination Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
CLO22-042: Long Survival in Small-Cell Lung Cancer With Central Nervous System Metastasis: Relationship Between Survival and Metastasis Chronology (SMALLBRAIN Project)
CLO22-043: Humoral Immune Response Following COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Large, Single-Center Observational Study
CLO22-045: Gastrointestinal Safety Profile of Sonic Hedgehog Inhibitors in Basal Cell Carcinoma (BCC): A Systematic Review and Meta-analysis
CLO22-046: A Prospective Study Comparing Acute Toxicities With Three Dimensional Conformal Radiation Therapy versus Intensity Modulated Radiation Therapy in Carcinoma Cervix Patients at a Tertiary Cancer Center
CLO22-047: Outcomes of SARS-COV-2 mRNA-1273 Vaccine in Cancer Patients: Seroconversion and Adverse Events
CLO22-048: Treatment Outcomes of Metastatic Urothelial Cancer on Immune Checkpoint Inhibition
CLO22-049: Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation is Higher for Older Patients
CLO22-050: Hospitalization and Supportive Care Medication (SCM) Utilization in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) in EMPOWER-Lung 1
CLO22-051: Influence of Environmental Temperature on Pathological Complete Response and Overall Survival in Breast Cancer: A National Cancer Database Population-Based Study
CLO22-052: A Tale of Two Schedules: A Study of the Efficacy and Toxicity Outcomes of Extended Durvalumab Dosing in Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
CLO22-053: Risk Factors of Paclitaxel Induced Peripheral Neuropathy in Early Breast Cancer Patient in Relation to Mean Changes of Neuropathy Growth Factors and Serum Malondialdehyde
CLO22-054: A Pilot Study of Liquid Biopsy Utility in De-escalation Therapy for HPV-Associated Oropharyngeal Cancer
CLO22-055: Breast Cancer in Men: Experiences of Men With Breast Cancer in One of the Largest Hospital in Riyadh, KSA
CLO22-056: Phase I Trial of Concurrent Nab-paclitaxel and Cisplatin With Radiotherapy for Locally Advanced Cervical Cancer
CLO22-057: A Rare Case of Intravascular Lymphoma Presenting With Dyspnea and Bilateral Lung Infiltrates
CLO22-058: Sex Differences in Pain Relief From Medical Cannabis in Patients With Cancer: Results From the Quebec Cannabis Registry
CLO22-059: Chemotherapy Timing and Outcomes in Early Breast Cancer
CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients
CLO22-061: c-MET Alteration in Patients With Metastasized Colorectal Carcinoma – An Evaluation of Methods of Detection, Clinical Impact and Discussion of c-MET as Potential Therapeutic Target
CLO22-062: The Impact of COVID-19 Infection Among Genitourinary Cancer Patients in Los Angeles County: A Retrospective Analysis
CLO22-063: Study on Correlation Between Serum CA 19-9 and Colorectal Carcinoma With Normal CEA
CLO22-064: Presurgical Edema Volume Influences the Decision to Perform a Biopsy or a Complete Resection in Glioblastoma Patients
CLO22-065: Treatment Failure and Transition to Next-Line Therapy in Myelofibrosis: A Modified Delphi Panel Approach
CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population
CLO22-067: Symptom Burden in Patients With Myelofibrosis who Have Moderate or Severe Thrombocytopenia: A Retrospective Analysis of Patients Enrolled in the PERSIST-2 Study
CLO22-068: An Assessment of Extended Pembrolizumab Dosing and Outcomes in Advanced Non-Small Cell Lung Cancer Patients During the COVID-19 Pandemic
CLO22-069: Radiation Induced Lymphopenia (RAILs on Time Saves Nine!) In Carcinoma Esophagus!
CLO22-070: Study of Molecular Biological Predictors of Recurrence of Endometrioid Type of Endometrial Cancer Stage I
CLO22-071: Does Tumor Site Have Independent Prognostic Ability in Breast Cancer? A Deep Learning Approach
CLO22-073: Familial Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Associated to Novel PTCH1 Mutation c.1067 + 2T>C of Paternal Origin in Somatic Mosaicism With Marked Phenotypic Variation in the Children
CLO22-074: Patient-Reported Outcomes (PROs) in Patients (pts) With Advanced Non-Small Cell Lung Cancer (aNSCLC) With Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation
CLO22-075: Hereditary Retinoblastoma: Same Disease, Different Aetiologies
CLO22-078: Dual-Tracer PET/CT-Targeted, mpMRI-Targeted, Systematic Biopsy, and Combined Biopsy for the Diagnosis of Prostate Cancer
CLO22-079: A Phase II Open-Label Study of Subcutaneous CpG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer
CLO22-080: Correlation of Imaging and Biochemical Modalities in Identifying the Exact Anatomical Site of Origin of Tumour in Periampullary Carcinoma – A Prospective Observational Study
CLO22-081: Clinical Efficacy and Quality of Life of Oral Cancer Patients Treated With Paclitaxel/Cisplatin/5-FU Vs Paclitaxel/Carboplatin Chemotherapeutic Regimens in a Tertiary Cancer Center in Eastern India
CLO22-082: Texture Feature Analysis With C11 Methionine in Glioma on Simultaneous PET/MRI
CLO22-083: Impact of Body Mass Index (BMI) on the Unplanned Need for Whole Breast Radiation Therapy (WBRT) Following Intra-Operative Electronic Brachyterapy for Early-Stage Breast Cancer
CLO22-084: Real-World Comparison of Regorafenib and Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer: A Multicenter Retrospective Analysis With Focus on Elderly Patients Subgroup
CLO22-085: A Dual-Center Retrospective Cohort Validation of the 2021 NCCN Risk Stratification for Cutaneous Squamous Cell Carcinoma
CLO22-086: A Phase 2, Multi-Arm Study of Anti-CD47 Antibody Magrolimab in Combination With Docetaxel in Patients With Locally Advanced or Metastatic Solid Tumors
CLO22-087: Safety and Effectiveness of Continuous Denosumab for Unresectable or Advanced Giant Cell Tumor: Monthly and Once Every Three Months Regimen
CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)
CLO22-089: BC200 Mediates Immune Escape in NSCLC by Affecting Tumor-Immune Microenvironment
CLO22-090: Patient Characteristics, Treatment Patterns, and Clinical Outcomes of Patients With Advanced HER2-Low Breast Cancer
CLO22-091: Malignancy or Not? Role of 18F-FDG PET/CT in Solving the Diagnostic Dilemma in Multiple Myeloma Misdiagnosed as Rheumatoid Arthritis: Pictorial Series
CLO22-092: Prostate Cancer With Osteolytic Bone Metastasis on 68GaPSMA PET/CT: Staging and Response Assessment
CLO22-093: The Incremental Role of 18F-FDG PETCT in Staging and Response Assessment in Ewing Sarcoma Family Tumors
CLO22-094: Leg Length Discrepancy Following Limb Sparing Surgery in Pediatric and Adolescent Lower Extremity Bone Sarcomas: A Case Series
Correlative/Genomic
CGE22-095: CCND1 Amplification in Pancreatic Ductal and Ampullary Adenocarcinoma and Its Impact on Patients’ Survival: A Single Centre Observational Study
CGE22-096: Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 in the United States: Findings From the SEQUENCE Study
CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical Trials
CGE22-098: Correlation Between Trough Level of Abiraterone Acetate and PSA Response in Metastatic Hormone Sensitive Prostate Cancer
CGE22-100: Community Oncologists’ Current and Future Patterns of Germline Testing for Patients With Early-Stage Breast Cancer
CGE22-101: Dynamically Accumulating Homologous Recombination Deficiency (HRD) Status Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer
CGE22-103: Identifying Patients at Risk for Hereditary Myeloid Malignancy Syndromes Using a Self-Administered Questionnaire as an Initial Screening Tool: A Single Center Experience
Epidemiology/Risks/Prevention
EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019
EPR22-105: Relationship of Age, Education, and Duration of Lump on Stage at Presentation in Breast Cancer Patients: A Pilot Study From a Low Middle-Income Country
EPR22-106: Decelerating Decline and Urban-Rural Differences for Gastrointestinal Cancer Mortality in the United States, 1999-2019
EPR22-107: Evaluation of Early Risk of Moderate-to-Severe Cytokine Release Syndrome (CRS) Induced by CAR T-cell Therapy Using Pooled Clinical Trial Data
EPR22-108: The Effect of Advances in Uterine-Cancer Treatment on Population Mortality
EPR22-109: Cancer Incidence in Immunocompromised Patients
EPR22-111: Outcomes and Utilization of Adjuvant Chemotherapy With and Without an Anthracycline in Node-Positive, Triple-Negative Breast Cancer: Analysis of SEER-Medicare Data
EPR22-112: Risk of Prostate Cancer for Metformin Versus Sulphonylurea Monotherapy in Type 2 Diabetes Mellitus: A Propensity Score-Matched Retrospective Cohort Study
EPR22-113: Awareness, Utilization, and NCCN Guideline-Adherence to Breast Cancer Risk Management Behavior Among a Community-Based Sample of High-Risk Women
EPR22-114: Acceptance of SARS-CO-2 Vaccination Among Cancer Patients: Experience of Radiation Therapy Center in Tunisia
EPR22-115: Reporting of Race and Ethnicity in AL Amyloid Clinical Trials
EPR22-117: Evaluation of the Influence of the BRAF V600E Mutation and of the Microsatellite Instability on the Overall Survival (OS) of Metastatic CRC Patients Based on Real World Data
EPR22-118: Incidence of Herpes Zoster in Immunocompromised Individuals and Zoster Vaccination as an Effective Preventative Strategy
EPR22-119: Cost-Effectiveness of Multi-Cancer Early Detection (MCED) Test in Subgroups With Smoking History or Obesity
EPR22-120: The Evolving Landscape of Rural Population Survival in Invasive Colon Cancer
EPR22-121: Racial Disparities in Survival Outcomes Among Patients With Appendiceal Cancer
Outcomes and Health Services Research
HSR22-122: Racial Disparities in Breast Cancer-Specific Survival Among Women Aged 40 Years or Younger in the United States
HSR22-123: Breaking Cost Barriers in Treatment With Biosimilars–Improvement in Affordability of Trastuzumab Against HER2 Positive Breast Cancer Amongst Indian Women
HSR22-124: Real-World Outcomes Among Patients With Stage IV Epidermal Growth Factor Receptor (EGFR) Mutated Non-Small Cell Lung Cancer Treated With EGFR Tyrosine Kinase Inhibitors Versus Immunotherapy With or Without Chemotherapy in First-line Setting
HSR22-125: Quality of Gastrointestinal Surgical Oncology Care According to Insurance Status
HSR22-126: Key Factors Associated With Breast Cancer Clinical Trial Enrollment in Underrepresented Minority Groups
HSR22-128: Patient-Level Barriers to Surveillance for Hepatocellular Carcinoma Among Patients With Chronic Liver Disease From the Provider Perspective
HSR22-129: The Cost of Treatment of HR+/HER2- Early Breast Cancer and Implications for the Cost-Effectiveness of Multigene Assays in the US
HSR22-130: A Retrospective Cohort Study of Selpercatinib-Treated Patients With Advanced/Metastatic Non-Small Cell Lung Cancer: Preliminary Findings From a Real-World Database in the United States
HSR22-131: Incremental Health Care Costs of Anxiety and Depression Among Medicare Beneficiaries With Cancer
HSR22-132: Evolution of an Advanced Practice Provider (APP) Clinical Advancement Program (CAP): From Development and Implementation to Present
HSR22-134: Outcomes of Patients who Received Radiation Therapy for Brain Metastases From Gynecologic Malignancies
HSR22-135: Telemedicine for Cranial Radiosurgery Patients in a Rural US Population: Patterns and Predictors of Patient Utilization
HSR22-136: Productivity Loss Associated With Late Versus Early Stage Cancer Diagnosis
HSR22-137: Proton Radiotherapy Utilization for Patients Diagnosed in 2018: A National Cancer Database Analysis
HSR22-138: Oncologist’s Perceptions on Immune Checkpoint Inhibitor Therapies for Non-Small Cell Lung Cancer
HSR22-139: Augmented Intelligence to Reduce Oncology Care Model (OCM) Unplanned Admissions
HSR22-140: Patient Preferences for Multi-Cancer Early Detection Tests: A Discrete Choice Experiment (DCE)
HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy
HSR22-142: A Review of Lung Cancer Screening Compliance in a Federally Qualified Health Center: Uncovering Unconscious Bias
HSR22-143: Outcome Differences Amongst Stage-Matched Inflammatory vs Non-Inflammatory Breast Cancer Patients
HSR22-144: Survival Difference of EGFR Exon 19 Deletion and Exon 21 Mutation in Asian Patients With Advanced Non-small Cell Lung Cancer
HSR22-145: Pembrolizumab Plus Chemotherapy for First-Line Treatment of Advanced Triple-Negative Breast Cancer – A Network Meta-Analysis
HSR22-146: Health Utility in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
HSR22-147: Experiences of Patients (pts) With Metastatic Breast Cancer (mBC) During the COVID-19 Pandemic in the United States: Results of the Rethink Access to Care & Treatment (REACT) Survey
HSR22-148: Prevalence of Social Toxicity and Associated Factors Among Patients With Cancer in Saudi Arabia
HSR22-149: Adverse Events Among Cancer Patients Treated With a Combination of Nivolumab and Ipilimumab as Compared to Nivolumab Monotherapy: A Systematic Review and Meta-Analysis
HSR22-150: Lymph Node Evaluation of Post-Neoadjuvant Rectal Resection Specimens in Rectal Carcinoma
HSR22-151: Access to Care and Health Care Quality Metrics in Urban Versus Rural Patients With Advanced Genitourinary Cancers
HSR22-152: Healthcare Resource Utilization, Dosing and Time on Treatment in Patients on Pexidartinib Tenosynovial Giant Cell Tumors: Real-World Evidence from a Claims-Based Dataset
HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
HSR22-154: Treatment Patterns Following Osimertinib Discontinuation in Patients With EGFR Mutated Metastatic NSCLC
HSR22-155: Management of Close/Positive Margins in cSCCHN
HSR22-156: Patient Perspectives on Progression-Free Survival and Quality of Life in Metastatic Breast Cancer
HSR22-157: We Answered the Call to Continue Colorectal Cancer Screening of Disparate Patients Despite COVID-19
HSR22-158: Managing Diabetes Mellitus During Cancer Treatment: The Missing Link to Primary Care
HSR22-159: Hip Transposition With the Use of Prophy Ethylene Mesh as a Reconstructive Option After Pelvic Resection of Periacetabular Bone Tumor: A Case Series
HSR22-160: An Assessment of the Association Between Patient Race and Prior Authorization Program Determinations in the Context of Radiation Therapy for Breast Cancer
HSR22-161: Racial Disparities in Stage 1 Lung Cancer Treatment
HSR22-162: Budget Impact Analysis of Abemaciclib in Combination With Endocrine Therapy (ET) in Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-), Node-Positive Early Breast Cancer (EBC) at High Risk of Recurrence and Ki-67 Score ≥20%
HSR22-163: Real World Data and Independent Predictors of Clinical Outcomes with CDK Inhibitors in Metastatic ER+ Breast Cancer Patients
HSR22-164: Laparoscopic Versus Open Gastrectomy: Is There a Difference in the Number of Lymphatic Nodes Harvested?
HSR22-165: Pulmonary Function Tests (PFTs) and Immune Checkpoint Inhibitor Pneumonitis
HSR22-166: Patient Demographic and Socioeconomic Differences in Non-Small Cell and Small Cell Lung Cancers: Impact on Outcomes. A National Cancer Database Analysis.
HSR22-167: Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy in a Community Oncology Setting
HSR22-168: Patient Satisfaction and Reason for Discontinuation of Home Infusion for Cancer Patients
HSR22-169: Predictors for In-Hospital Mortality in Patients With Malignant Ascites Who had DNR Code Status
HSR22-170: Risk Factors for 30-Days Readmission in Pancreatic Cancer With Hospice
HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)
HSR22-172: Immunogenicity of ChAdOx1-nCoV-19 Vaccination for Solid Cancer Patients, Prospective Observational Multicenter Study - Preliminary Report
HSR22-173: Treatment Patterns, Healthcare Resource Use and Costs Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer Following Discontinuation of Osimertinib and Platinum-Based Chemotherapy
HSR22-174: Are We ‘Choosing Wisely’? A Case of Unnecessary Staging Imaging in Older Patients With Prostate Cancer
HSR22-175: Impact of ‘Choosing Wisely’ on Unnecessary Staging Imaging in Patients With Early Stage Breast Cancer: A Seer-Medicare Analysis
HSR22-176: Medication Adherence and Subsequent Healthcare Resource Utilization Among Patients With Cancer Newly Initiating Their Oral Anticancer Medication
HSR22-177: Real-World Utilization of Lenvatinib+Pembrolizumab Combination Therapy for the Treatment of Advanced Endometrial Cancer in the United States: ENdometrial cancer DOsing in the real-World (ENDOW) Study
HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies
HSR22-179: Treatment Patterns of Patients With Soft Tissue Sarcoma Progressing to Third Line of Therapy
HSR22-180: Real-World Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy in BRAF+ Cutaneous Melanoma Patients Treated in the Adjuvant Setting
HSR22-181: CancerSupportSource®-Caregiver: Development of a Multidimensional Distress Screening Measure for Family and Informal Cancer Caregivers
HSR22-182: Real-World Treatment Patterns Among Patients With Sézary Syndrome in the United States Between 2018 and 2020
HSR22-183: Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures
HSR22-184: The Association of the Social Vulnerability Index to Timely Treatment of Metastatic Cancers Among Insured Adult Patients in the US
Pre-Clinical Oncology
Quality Improvement
QIM22-189: Harnessing Pathway Power: Development of a Clinical Pathway Program in a Comprehensive Cancer Center for Improved EOL Care and Beyond
QIM22-190: Virtual Patient Navigation: A Revised Navigation Strategy Proves Successful at Completing CRC Screening in Vulnerable Populations
QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes
QIM22-192: Mismatch Repair Protein Immunohistochemistry: Quality of Mismatch Repair Deficiency Detection
QIM22-193: Development and Implementation of a Scheduling Tool to Improve Patient Access to Outpatient Care in an Academic Cancer Center
QIM22-194: Using the Merlin Assay to Reduce Sentinel Lymph Node Biopsy Rates and Its Complications: A Retrospective Cohort Study
QIM22-195: Oncology Patients Experience With Informed Consent: The Need to Optimize the Process
QIM22-196: Participation in a Mentored Cancer Quality Improvement Collaborative Improves QI Aptitude Among Oncology Providers
QIM22-197: Protected Time and Provision of Resources at National Comprehensive Cancer Network (NCCN) Member Institutions (MIs)
QIM22-198: Optimizing a Systemic Platform to Standardize Oncologic Biosimilars Utilization at Cedars-Sinai Medical Center (CSMC)
QIM22-199: Descriptive Information on Classification of Patients With Lymphedema Into Homogenous Patient Subgroups
QIM22-200: Survivorship Care Plan (SCP): A Continuum After Successful Cancer Treatment
QIM22-201: Experiences With Cancer Diagnosis and Treatment in Rural Nebraska: Qualitative Focus Group Analysis
QIM22-202: Cancer Diagnostic Center: A Response to the COVID-19 Pandemic to Improve Access to Diagnostic Testing
QIM22-203: Randomized Trial of Implementing a Clinical Decision Support Tool for Automatic Selection of Payor-Mandated Biosimilar at Time of Prescribing
QIM22-204: A Retrospective Analysis and Quality Improvement Project to Increase Breast Cancer Screening in Northwestern Medicine Hospital, Internal Medicine Residency Clinic
QIM22-205: Implementation of a Comprehensive Pre-Habilitation Program for Patients Undergoing Radical Cystectomy
QIM22-206: Physical Therapy Outcomes in Oncology Multidisciplinary Clinics
QIM22-207: Physical Therapy Assessment for Management of Breast Cancer Related Lymphedema After Axillary Lymph Node Dissection
  • Collapse
  • Expand